ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S - CVR: 32323502

2023, EUR

03.04.2024

Bruttoresultat

-8.329'

Primær drift

-8.419'

Årets resultat

-8.090'

Aktiver

6.733'

Kortfristede aktiver

6.733'

Egenkapital

6.725'

Afkastningsgrad

-125 %

Soliditetsgrad

100 %

Likviditetsgrad

+500%

Resultat

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Nettoomsætning
Bruttoresultat	-8.328.991	0	-30.400	-1.850	7.218	257.277	3.244.713	5.370.361
Resultat af primær drift	-8.418.532	-94.082	-125.713	-120.628	-111.447	138.825	3.126.781	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	320.749	365.045	358.574	351.276	483.764	181.408	689.100	796.628
Finansieringsomkostninger	-352	-77	-374	-282	-1.146	-799.988	-246.249	-335.244
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	-8.098.135	270.886	232.487	230.366	371.171	-479.755	3.569.632	5.715.157
Resultat	-8.089.721	213.018	196.963	210.420	371.171	-479.755	3.444.680	5.606.878
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	6.721.754	14.804.521	14.590.036	14.406.324	13.966.175	6.913.179	8.325.321	9.768.277
Likvider	11.627	17.061	21.654	5.620	235.216	6.916.863	6.067.053	4.145.164
Kortfristede aktiver	6.733.381	14.821.582	14.611.690	14.411.944	14.201.391	13.830.042	14.392.374	13.913.441
Immaterielle aktiver og goodwill	0	0	0	0	0	0	11.185	22.370
Finansielle anlægsaktiver	0	0	0	0	0	0	0	0
Materielle aktiver	0	0	0	0	0	0	0	0
Langfristede aktiver	0	0	0	0	0	0	11.185	22.370
Aktiver	6.733.381	14.821.582	14.611.690	14.411.944	14.201.391	13.830.042	14.403.559	13.935.811

Aktiver

03.04.2024

Passiver

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	6.724.506	14.814.227	14.601.209	14.404.246	14.193.826	13.822.655	14.302.410	10.857.730
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	0	0	0	0	0	0	0	0
Kortfristede forpligtelser	8.875	7.355	10.481	7.698	7.565	7.387	101.149	3.078.081
Gældsforpligtelser	8.875	7.355	10.481	7.698	7.565	7.387	101.149	3.078.081
Forpligtelser	8.875	7.355	10.481	7.698	7.565	7.387	101.149	3.078.081
Passiver	6.733.381	14.821.582	14.611.690	14.411.944	14.201.391	13.830.042	14.403.559	13.935.811

Passiver

03.04.2024

Nøgletal

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Afkastningsgrad	-125,0 %	-0,6 %	-0,9 %	-0,8 %	-0,8 %	1,0 %	21,7 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-120,3 %	1,4 %	1,3 %	1,5 %	2,6 %	-3,5 %	24,1 %	51,6 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-2.391.628,4 %	-122.184,4 %	-33.613,1 %	-42.775,9 %	-9.724,9 %	17,4 %	1.269,8 %	Na.
Soliditestgrad	99,9 %	100,0 %	99,9 %	99,9 %	99,9 %	99,9 %	99,3 %	77,9 %
Likviditetsgrad	75.869,1 %	201.517,1 %	139.411,2 %	187.216,7 %	187.724,9 %	187.221,4 %	14.228,9 %	452,0 %

Resultat

03.04.2024

Gæld

03.04.2024

Årsrapport

03.04.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 03.04.2024)

Beretning

03.04.2024

Dato for ledelsens godkendelse af årsrapporten:2023-02-24

Oplysning om usædvanlige forhold:As reported in the financial statements as of and for the year ended December 31, 2021, a novel strain of coronavirus, (“COVID-19”), was reported to have surfaced in Wuhan, China, in December 2019. Since then, COVID-19 has spread around the world into a pandemic. Since COVID-19 started to spread around the world, we have closely monitored the development, and implemented several measures to accommodate any potential negative impact on our business. Activities in 2022 have been limited, and accordingly, COVID-19 did not had a significant impact on the Company. We monitor potential COVID-19 related risks closely, and address these risks as they may become relevant, including collaborating with relevant stakeholders to avoid disruptions, and to develop and establish working measures. However, while COVID-19 continues to impact global societies, the uncertainty related to the duration and direction of the pandemic makes the future impact from COVID-19, including the magnitude on the operational results, highly uncertain and cannot be reliably predicted.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Executive Board and Board of Directors have today considered and adopted the Annual Report of Ascendis Pharma, Ophthalmology Division A/S for the financial year 1 January - 31 December 2022.